Therapeutic Strategies against Ebola Virus Infection

Ching Hsuan Liu, Yee Tung Hu, Shu Hui Wong, Liang Tzung Lin

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.

Original languageEnglish
Article number579
Issue number3
Publication statusPublished - Mar 1 2022


  • Antiviral
  • Drug development
  • Ebola virus
  • Ebola virus disease
  • Therapeutic

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Therapeutic Strategies against Ebola Virus Infection'. Together they form a unique fingerprint.

Cite this